EMA ‘Needs More Resources’ If EU Rolling Reviews Are To Be Used More Widely
Executive Summary
An assessment of the European Medicines Agency’s performance in tackling the COVID-19 pandemic shows that the agency was “well prepared” with a crisis management plan but that it faced a range of challenges such as the fallout from Brexit, a heavy workload and how to maintain the public’s trust in medicines regulation.
You may also be interested in...
Noël Wathion, Former EMA Deputy Executive Director, Dies Aged 66
The European Medicines Agency said Noël Wathion, who retired two years ago, will be remembered for steering the agency through challenges such as Brexit and COVID-19, in addition to being a champion of transparency and public engagement.
Noël Wathion, Former EMA Deputy Executive Director, Dies Aged 66
The European Medicines Agency said Noël Wathion, who retired two years ago, will be remembered for steering the agency through challenges such as Brexit and COVID-19, in addition to being a champion of transparency and public engagement.
EU’s Unitary SPC System Must Maximize Access To Medicines & Not Block Generic Entry
A European Parliament committee says that some aspects of the EU’s proposed unitary supplementary protection certificate scheme could promote access to cheaper off-patent medicines while others could delay generic competition.